# Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT01549951** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Orteronel+Prednisone

## Key facts

- **NCT ID:** NCT01549951
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01549951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01549951, "Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01549951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*